Clinica Baviera S.A. (0GWJ)
London Exchange · UK · prices in EUR · close of 20 Oct 2026
Key indicators
| Last close | EUR 54.20 |
|---|---|
| 52-week range | 39.25 – 62.00 |
| Return, 1 month / 3 months | −4.6% / −7.2% |
| Return, 1 year / 3 years | +33.4% / – |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 38 |
| Volatility (1 year) | 27.3% |
| Worst drawdown (1 year) | -13.6% |
| Average daily value traded | 0.03M EUR |
| Dividend yield | 2.3% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Clinica Baviera is a Spanish group of ophthalmology clinics that provides eye care and vision correction services. Its clinics offer treatments such as laser refractive surgery, cataract operations and other procedures for conditions affecting eyesight. The company serves private patients who pay for consultations and surgery, and it operates a network of centres across Spain and in several other European countries. It is based in Valencia, Spain.
Clinica Baviera S.A. trades under the code 0GWJ on the London Exchange in UK, with its price quoted in euros (EUR). Our dividend records, which start in 2019, show payments in 7 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Clinica Baviera S.A. (0GWJ) trades on the London Exchange in UK. It last closed at EUR 54.20 on 20 October 2026.
Its price-based Market X-Ray is 60 out of 100 (a fair price profile), ranking 1,329 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 33.4% and over the last three months it fell 7.2%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 60 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 0.2% | ||
| From 52-week high | -11.7% | ||
| Momentum | 59 · Fair | Typical recent returns for this exchange. | |
| 3-month return | -7.2% | ||
| 6-month return | 7.3% | ||
| 12-month return, skipping the last month | 39.8% | ||
| Stability (higher is calmer) | 79 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 27.3% | ||
| Worst drawdown, 1 year (smaller is calmer) | -13.6% | ||
| Liquidity | 19 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.03M EUR | ||
| Zero-volume days | 13.3% | ||
| Income | 74 · Strong | Dividend is high and has been paid regularly. | |
| Dividend yield | 2.3% | ||
| Years with dividends | 6 |
Strengths
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
- Income: Dividend is high and has been paid regularly.
Weak spots
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | −1.1% |
|---|---|
| 1 month | −4.6% |
| 3 months | −7.2% |
| 6 months | +7.3% |
| 1 year | +33.4% |
| 3 years | – |
| 5 years | – |
Signals
| 50-day / 200-day average | 57.42 / 54.08 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 1.09 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 10 Jun 2026 | EUR 1.2717 |
| 11 Jun 2025 | EUR 1.2717 |
| 16 Jul 2024 | EUR 1.2717 |
| 31 May 2023 | EUR 0.6480 |
| 14 Dec 2022 | EUR 0.4050 |
| 25 May 2022 | EUR 0.4293 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.